PharmaLundensis is a research company. Main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution. PharmaLundensis is based in Lund.

Quotes for PharmaLundensis AB

Right Now

+/-
-0.004
%
−1,04%
Latest
0.38
High
0.38
Low
0.38
Volume
13 450
Turnover (SEK)
5 111
Market Value (MSEK)
19,2
Time (Latest trade)
2024-11-21 14:33

Board

CEO

  • Staffan Skogvall

Chairperson of the Board

  • Arne Skogvall

Board

  • Bo Wennergren
  • Björn Sivik
  • Staffan Skogvall
  • Stefan Ahlfors

Largest Owners

Name Capital % Votes % Date
Staffan Skogvall 45,57 45,57 2024-10-14
Vict Th Engwalls Stiftelse 2,29 2,29 2024-09-26
Avanza Pension 1,51 1,51 2024-09-26
Arne Arvidsson 1,43 1,43 2024-09-26
Nordnet Pensionsförsäkring 0,81 0,81 2024-09-26
Tommy Johansson 0,71 0,71 2024-09-26
Staffan Engelbert Bodén 0,64 0,64 2024-09-26
Magnus Persson 0,55 0,55 2024-09-26
Merrick Lee Tabor 0,53 0,53 2024-09-26
Arne Skogvall 0,52 0,52 2024-09-26
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

*Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2024-11-21 Delårsrapport 2024-Q3

  • 2025-02-20 Bokslutskommuniké 2024